| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7378423 | NOVARTIS | Pyrimidine compound and medical use thereof |
May, 2027
(3 years from now) | |
| US8703781 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835443 | NOVARTIS | Pyrimidine compound and medical use thereof |
Jun, 2025
(1 year, 1 month from now) | |
|
US8835443 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Dec, 2025
(1 year, 7 months from now) | |
|
US7378423 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Nov, 2027
(3 years from now) | |
| US8952018 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Oct, 2030
(6 years from now) | |
|
US8952018 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Apr, 2031
(6 years from now) | |
|
US8703781 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Apr, 2031
(6 years from now) | |
| US9399021 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(7 years from now) | |
| US9271941 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(7 years from now) | |
| US8580304 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(7 years from now) | |
| US9155706 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(7 years from now) | |
|
US9155706 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
|
US9271941 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
|
US8580304 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
|
US9399021 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
| US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(9 years from now) | |
|
US10869869 (Pediatric) | NOVARTIS | Method of adjuvant cancer treatment |
Mar, 2034
(9 years from now) | |
Mekinist is owned by Novartis.
Mekinist contains Trametinib Dimethyl Sulfoxide.
Mekinist has a total of 18 drug patents out of which 0 drug patents have expired.
Mekinist was authorised for market use on 29 May, 2013.
Mekinist is available in tablet;oral, solution;oral dosage forms.
Mekinist can be used as mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test, in combination with dabrafenib for the treatment of unresectable or metastatic melanoma., mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection, mekinist is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test.
Drug patent challenges can be filed against Mekinist from 22 December, 2024.
The generics of Mekinist are possible to be released after 02 March, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| Orphan Drug Exclusivity(ODE-148) | Jun 22, 2024 |
| New Indication(I-908) | Mar 16, 2026 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
| New Indication(I-895) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Dec 22, 2025 |
| New Indication(I-745) | Jun 22, 2020 |
| Orphan Drug Exclusivity(ODE-48) | May 29, 2020 |
| M(M-170) | Nov 20, 2018 |
| Orphan Drug Exclusivity(ODE-57) | Jan 08, 2021 |
| New Indication(I-678) | Jan 08, 2017 |
| M(M-246) | Oct 06, 2022 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
NCE-1 date: 22 December, 2024
Market Authorisation Date: 29 May, 2013
Treatment: In combination with dabrafenib for the treatment of unresectable or metastatic melanoma.; Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small...
Dosage: TABLET;ORAL; SOLUTION;ORAL
MEKINIST family patents
